Long-Term Outlook for Aortic Valve Replacement

The management of severe aortic stenosis has undergone a paradigm shift since the introduction of transcatheter aortic valve replacement (TAVR). Initially reserved for patients deemed inoperable or high-risk, TAVR is now frequently considered for younger and lower-risk populations. This expansion necessitates a rigorous evaluation of TAVR vs surgery durability, as younger patients require bioprostheses that can withstand several decades of mechanical stress. The PARTNER 3 trial was specifically designed to address these concerns by comparing the balloon-expandable SAPIEN 3 TAVR system with traditional surgical aortic valve replacement (SAVR) in low-risk cohorts. Clinicians in India and globally have eagerly awaited long-term data to guide lifetime management strategies for these patients. The seven-year results provide essential clarity regarding the performance of these valves beyond the early post-operative period. These findings help doctors determine whether the less invasive nature of TAVR compromises the long-term integrity of the heart valve.

Methodology and Patient Demographics in PARTNER 3

The PARTNER 3 randomized clinical trial enrolled 1,000 patients across 71 centers in the United States and Canada between March 2016 and October 2017. Participants were randomized to undergo either TAVR with the SAPIEN 3 valve or SAVR with any commercially available surgical valve. The primary analysis for this seven-year follow-up included 495 patients in the TAVR arm and 453 in the surgical arm who successfully underwent valve implantation. The mean age of the participants was approximately 73.5 years, representing a population that is younger than traditional TAVR cohorts but still carries significant long-term survival potential. Furthermore, 69.3% of the participants were male. By the seven-year mark, which concluded in March 2025, 537 patients remained available for detailed echocardiographic analysis. Researchers utilized standardized definitions from the Valve Academic Research Consortium (VARC) to assess outcomes. Specifically, they measured structural valve deterioration (SVD), bioprosthetic valve failure (BVF), and the incidence of endocarditis or thrombosis-related dysfunction. This robust design ensures that the comparative data is statistically significant and clinically applicable for practitioners managing heart valve disease.

Structural Valve Deterioration and Hemodynamic Performance

One of the primary concerns when evaluating TAVR vs surgery durability is the rate of structural valve deterioration. In this seven-year analysis, the cumulative incidence of Stage 2 or 3 SVD-related bioprosthetic valve dysfunction was remarkably similar between the two groups. Specifically, the rates were 7.3% for the TAVR group and 7.6% for the surgical group. The hazard ratio of 0.96 (95% CI, 0.59-1.57; P = 0.88) clearly indicates that there is no significant statistical difference in structural integrity over this timeframe. Hemodynamic performance remained stable in both cohorts, with low mean aortic-valve gradients and adequate valve areas maintained throughout the follow-up period. Moreover, the trial observed that the balloon-expandable TAVR valve did not show accelerated wear compared to surgical bioprostheses. This finding is particularly reassuring for interventional cardiologists who recommend TAVR to low-risk patients. It suggests that the mechanical stresses involved in the transcatheter deployment of the SAPIEN 3 valve do not lead to premature tissue fatigue compared to the direct visualization and suturing associated with surgery.

Assessing TAVR vs Surgery Durability: Failure and Reintervention

Beyond structural deterioration, clinicians must monitor for bioprosthetic valve failure (BVF) and the need for reintervention. All-cause BVF, which includes failure due to SVD, thrombosis, or endocarditis, occurred in 6.9% of TAVR patients and 7.5% of surgical patients (P = 0.69). When focusing specifically on SVD-related BVF, the rates were 3.9% and 5.3%, respectively. These low percentages underscore the high quality of modern bioprosthetic materials. Additionally, the rate of aortic valve reintervention remained comparable, with 6.0% of the TAVR group and 5.5% of the surgical group requiring a secondary procedure (P = 0.77). Consequently, these results mitigate fears that TAVR might lead to a higher volume of redo procedures in the first decade following implantation. While the study used death as a competing risk in its analysis, the survival rates were also similar between the two arms. For patients in India, where access to repeat cardiac surgery can be challenging, the fact that TAVR matches surgical reintervention rates over seven years provides a significant clinical advantage. This data supports the longevity of the transcatheter approach in well-selected low-risk individuals.

The Signal of Valve Thrombosis and Clinical Relevance

Despite the overall parity in durability, a distinct difference emerged regarding thrombosis-related bioprosthetic valve dysfunction. The seven-year analysis revealed that Stage 2 or 3 thrombosis occurred significantly more often in the TAVR group compared to the surgery group (5.2% vs 0.9%; HR, 5.52; P < 0.001). This includes both clinical and subclinical thrombosis detected via echocardiography. However, it is important to note that many of these cases did not immediately translate into adverse clinical events like stroke or heart failure. Furthermore, the higher incidence of thrombosis in the TAVR arm did not lead to a higher overall rate of valve failure during the study period. Researchers suggest that the differences in flow dynamics between transcatheter and surgical valves might contribute to this phenomenon. While this finding warrants continued surveillance, it has not yet altered the overall recommendation for TAVR in low-risk patients. Clinicians should remain vigilant for changes in valve gradients during routine follow-up, which may signal subclinical leaflet thrombosis that requires medical management with anticoagulation.

Future Implications for Lifetime Management

The PARTNER 3 trial's seven-year results represent a milestone in structural heart disease research. They demonstrate that for at least the first seven years, TAVR with the SAPIEN 3 system is non-inferior to surgery regarding valve durability and clinical outcomes. For younger patients, however, seven years is only a fraction of their remaining life expectancy. Therefore, while these results are encouraging, the medical community still requires ten- and fifteen-year data to fully understand the total lifespan of these devices. Lifetime management planning must consider the possibility of a TAVR-in-TAVR or a TAVR-in-SAVR procedure in the future. Additionally, the higher thrombosis rate in TAVR indicates a need for personalized antithrombotic strategies. In India, where patients may present at a younger age with rheumatic or bicuspid pathology, these findings must be interpreted with caution, as the trial primarily included elderly patients with tricuspid valves. Nevertheless, the PARTNER 3 data provides the most robust evidence to date that TAVR is a durable and effective option for low-risk patients requiring aortic valve replacement.

Frequently Asked Questions

Is TAVR as durable as open-heart surgery for aortic stenosis?

Based on the seven-year results of the PARTNER 3 trial, TAVR with the SAPIEN 3 valve shows comparable durability to surgical aortic valve replacement. The rates of structural valve deterioration and bioprosthetic valve failure were nearly identical between the two groups. This suggests that for low-risk patients, the transcatheter approach does not sacrifice long-term valve integrity compared to traditional surgery within the first seven years of follow-up.

Why is there a higher risk of valve thrombosis with TAVR?

The PARTNER 3 trial found that TAVR patients had a 5.2% incidence of valve thrombosis compared to 0.9% in the surgery group. This difference is likely due to the specific flow dynamics and leaflet geometry inherent in transcatheter valves. While most cases were subclinical, the higher rate suggests that TAVR leaflets may be more prone to thrombus formation. However, this did not lead to increased rates of valve failure or clinical complications.

What does this study mean for younger patients with aortic stenosis?

For younger, low-risk patients, the 7-year data is very encouraging, showing that TAVR remains a viable alternative to surgery with excellent durability. However, because these patients may live for another 20 to 30 years, they still require lifelong monitoring. The choice between TAVR and surgery should involve a Heart Team discussion, considering the potential need for future valve-in-valve procedures and the specific anatomical characteristics of the patient’s aortic root.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ternacle J et al. Seven-Year Valve Durability With Transcatheter or Surgical Aortic Valve Replacement: An Ad Hoc Analysis of the PARTNER 3 Randomized Clinical Trial. JAMA Cardiol. 2026 Jun 24. doi: 10.1001/jamacardio.2026.2299. PMID: 42340728.

Leon MB, Mack MJ, et al. Transcatheter or surgical aortic valve replacement in low-risk patients at seven years. N Engl J Med. 2025.

Pibarot P, et al. Structural valve deterioration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 trial. J Am Coll Cardiol. 2020;76(16):1830-1843.